novo nordisk ozempic - Search News

Order byBest matchMost fresh

Novo Nordisk slashes price of Ozempic

Novo Nordisk slashes price of Ozempic in half to $499 for cash-paying, eligible U.S. patients

Novo Nordisk has announced a sweeping reduction in the cost of its blockbuster diabetes drug Ozempic, cutting the monthly price for cash-paying U.S. patients with Type 2 diabetes from its previous list price of nearly $1,

· 15m

Novo Nordisk slashes price of Ozempic to $499 for cash-paying, uninsured patients

· 22h · on MSN

Novo Nordisk offers Ozempic at $499 per month to eligible US cash-paying customers

· 5h

US cash-paying customers can now get Ozempic for half price

The move comes as President Trump is pressuring drugmakers to lower drug costs.

· 5h

Health Canada approves Ozempic to reduce kidney decline in people with Type 2 diabetes

· 16h

US patients can now get Ozempic for half price if they can pay cash

· 11h

Diabetes drug Ozempic will cost half-price for US patients paying cash

The drug is available as an obesity medication under the alternate brand name Wegovy but will now be sold to patients with diabetes prescriptions as well.

· 13h

Novo Nordisk halves Ozempic price in US

· 16h

Inside the price war between Ozempic and other weight loss drugs

1don MSN

Why Novo Nordisk Stock Popped Monday

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, jumped 5% through 9:55 a.m. ET Monday on a series of positive announcements for its GLP-1 products.

3hon MSN

Canada approves Ozempic to cut risk of kidney failure, heart-related deaths

Canada has approved Novo Nordisk's diabetes drug, Ozempic, to cut chronic kidney disease progression and reduce the risk of kidney failure and heart-related deaths in type-2 diabetes patients, the company said Tuesday.

Canada approves Ozempic to reduce risk of diabetic kidney disease progression

Canada's health regulator has approved Novo Nordisk's diabetes drug, Ozempic, to reduce the risk of kidney failure and disease progression, as well as death due to heart problems in

The Pharma Letter3d

MASH win for Novo Nordisk’s Wegovy

Denmark’s Novo Nordisk scored a significant regulatory win for GLP-1drug Wegovy (semaglutide), as the US Food and Drug Administration (FDA) has approved an additional indication for the drug.